Resources

Jane Wall discusses investment in Alchemab Therapeutics, Life Sciences Sector Plan: one year on, regulatory and trade links, Women in Biotech and BIA members lounge

How we boost entry-level diversity up to the senior level

Applications are now open for BIA's 2027 Charity Partnership

Discover how BIA members influenced the UK Life Sciences Sector Jobs Plan, addressing critical biotech talent shortages, lab skills and AI innovation

Boyds, a leading global drug development consultancy, is pleased to announce the appointment of Laurence Skillern as Chief Medical Officer.

EnteroBiotix announced that the first patient has been dosed in RISE, its Phase 2b clinical trial evaluating EBX-102-02 in moderate-to-severe irritable bowel syndrome with constipation (IBS-C).

Coulter Partners successfully led a search for Salvia BioElectronics B.V. to place Jill Schiaparelli as Chair of its Board of Directors.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Chris Molloy on scale-up policy, improving treatments pipeline, LSSP, GMM regulation, LLSW, MDUK's Pedal Paddle Peak and Dr Sally Ann Forsyth OBE

Key takeaways as another BIA Summer Party 2026 delivers for the life sciences sector

The Global Talent visa route has been made easier for research-intensive businesses to attract international researchers and specialists

Myricx Bio reached agreement to be acquired by Novartis for up to $1.5 billion.

Astex has entered into an exclusive, worldwide research collaboration and license agreement with Genentech.

Brandon Capital announced the successful exit of its portfolio company Myricx Bio.

Craig Marshall, $1.5B OrganOx exit CEO, joins Oxford Medical Products board

The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.

Innovation Orbit 2026 is FI Group by EPSA’s international guide to grants, R&D tax credits and public incentives for businesses planning R&D, CAPEX, digital transformation or decarbonisation projects.

We must engage with the Chinese ecosystem – this is how

KQ Labs, a leading accelerator that has helped early-stage life sciences innovators raise over £230 million, is now accepting applications for its ninth programme